(Z)-2-Aethyl-3-methoxyacrylsaeureaethylester | 62142-23-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-2-Aethyl-3-methoxyacrylsaeureaethylester
• 英文别名: ethyl (2Z)-2-(methoxymethylidene)butanoate
• CAS: 62142-23-8
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: LVEHBHYDENJNPP-SREVYHEPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• TREATMENT OF CANCERS HAVING K-RAS MUTATIONS
  申请人：Curis, Inc.

  公开号：US20130102595A1

  公开（公告）日：2013-04-25

  The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

  本发明提供了一种治疗与K-ras突变相关的癌症的方法，适用于需要该方法的受试者。该方法包括以下步骤：（1）识别患有与K-ras突变相关的癌症的受试者；和（2）向受试者施用（i）PI3激酶抑制剂和（ii）HDAC抑制剂，其中PI3激酶抑制剂和HDAC抑制剂以联合治疗有效的剂量进行施用。
• Synthesis of beta-L-2-Deoxy nucleosides
  申请人：Novartis AG

  公开号：EP2157095A2

  公开（公告）日：2010-02-24

  An improved process for the preparation of 2'-modified nucleosides and 2'-deoxynucleosides, such as, β-L-2'-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2'-deoxynucleoside that may utilize different starting materials but that proceeds via a chloro-sugar intermediate or via a 2,2' anhydro-1-furanosyl-nucleobase intermediate. Where an 2,2'-anhydro-1-furanosyl base intermediate is utilized, a reducing agent, such as Red-Al, and a sequestering agent, such as 15-crown-5 ether, that cause an intramolecular displacement reaction and formation of the desired nucleoside product in good yields are employed. An alternative process of the present invention utilizes a 2,2'-anhydro-1-furanosyl base intermediate without a sequestering agent to afford 2'-deoxynucleosides in good yields. The compounds made according to the present invention may be used as intermediates in the preparation of other nucleoside analogues, or may be used directly as antiviral and/or antineoplastic agents.

  本发明提供了一种改进的方法，用于制备2'-修饰核苷和2'-去氧核苷，例如β-L-2'-去氧胸腺嘧啶（LdT）。特别是，改进的方法针对合成一种2'-去氧核苷，该方法可以利用不同的起始材料，但是通过氯代糖中间体或2,2'无水-1-呋喃基-核碱中间体进行。当使用2,2'-无水-1-呋喃基碱中间体时，采用还原剂（如Red-Al）和隔离剂（如15-冠-5醚），引起分子内位移反应并形成所需的核苷产物，产率良好。本发明的另一种替代方法利用无隔离剂的2,2'-无水-1-呋喃基碱中间体，以获得良好的2'-去氧核苷收率。根据本发明制备的化合物可以用作制备其他核苷类似物的中间体，或者可以直接用作抗病毒和/或抗肿瘤剂。
• PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20120088764A1

  公开（公告）日：2012-04-12

  The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

  本申请涉及基于锌结合基团的去氨嘌呤，噻吩嘧啶和呋喃嘧啶衍生物，以及它们在治疗与磷脂酰肌醇3-激酶相关的疾病和疾病，如癌症方面的用途。本申请还涉及治疗组蛋白去乙酰化酶相关疾病和与组蛋白去乙酰化酶和磷脂酰肌醇3-激酶相关的疾病。
• PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
  申请人：Cai Xiong

  公开号：US20130090335A1

  公开（公告）日：2013-04-11

  The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

  本发明提供了一种公式I的化合物，包括这种化合物的药物组合物以及在治疗与磷脂酰肌醇3-激酶相关的疾病和疾病，如癌症中使用这种化合物的用途。本申请进一步涉及治疗组蛋白去乙酰化酶相关疾病和与组蛋白去乙酰化酶和磷脂酰肌醇3-激酶相关的疾病。
• COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY
  申请人：Curis, Inc.

  公开号：US20180133223A1

  公开（公告）日：2018-05-17

  The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a BCL-2 inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and a BCL-2 inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a BCL-2 inhibitor and a pharmaceutically acceptable carrier or excipient.